SCHEMBL14769183

SCHEMBL14769183

CSc1ncc(C(=O)O)c(Cc2cccc(NC(=O)OC(C)(C)C)c2)n1

nearest known ligand 0.49

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SIRT2 Q8IXJ6 1/20 0.46
AURKA O14965 1/20 0.45
RPS6KB1 P23443 1/20 0.45
KMT2A Q03164 3/20 0.42
MEN1 O00255 2/20 0.42
MAPT P10636 2/20 0.42
ALDH1A1 P00352 3/20 0.40
SYK P43405 2/20 0.40
TOP2A P11388 1/20 0.40
TOP2B Q02880 1/20 0.40
LMNA P02545 1/20 0.39
MAPK1 P28482 1/20 0.39
HTT P42858 1/20 0.39
THRB P10828 2/20 0.39
NPSR1 Q6W5P4 1/20 0.39
TLR7 Q9NYK1 1/20 0.39
RXFP1 Q9HBX9 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14769152 0.92 KMT2A (0.47) SIRT2AURKARPS6KB1KMT2AMEN1
SCHEMBL14769153 0.89 HTT (0.51) SIRT2KMT2AMEN1MAPTALDH1A1
SCHEMBL14769185 0.85 RXFP1 (0.51) SIRT2AURKARPS6KB1KMT2AMEN1
SCHEMBL14772002 0.84 POLB (0.53) SIRT2AURKARPS6KB1MAPTLMNA
SCHEMBL13498135 0.81 SYK (0.55) SIRT2KMT2AMEN1MAPTALDH1A1
SCHEMBL2362528 0.80 ALDH1A1 (0.54) SIRT2KMT2AMEN1MAPTALDH1A1
SCHEMBL14769222 0.78 MAPT (0.42) SIRT2AURKARPS6KB1KMT2AMEN1
SCHEMBL27545443 0.77 THRB (0.52) KMT2AMEN1MAPTALDH1A1LMNA
SCHEMBL2288522 0.76 ALDH1A1 (0.57) SIRT2KMT2AMEN1MAPTALDH1A1
SCHEMBL29537763 0.75 SYK (0.55) KMT2AMEN1MAPTALDH1A1SYK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8710222-B2 2,4-disubstituted pyrimidines useful as kinase inhibitors CELGENE AVILOMICS RESEARCH, INC. (US) 2014-04-29 US disclosed
US-8710222-B2 2,4-disubstituted pyrimidines useful as kinase inhibitors CELGENE AVILOMICS RESEARCH, INC. (US) 2014-04-29 US disclosed
US-20130065899-A1 HETEROARYL COMPOUNDS AND USES THEREOF CELGENE AVILOMICS RESEARCH, INC. (US) 2013-03-14 US disclosed
US-20130065899-A1 HETEROARYL COMPOUNDS AND USES THEREOF CELGENE AVILOMICS RESEARCH, INC. (US) 2013-03-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130065899-A1 HETEROARYL COMPOUNDS AND USES THEREOF ABCG2, CYP3A43, CYP3A5 SIRT2 1770/4885AURKA 1849/4885RPS6KB1 3635/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.